Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sollievo is a phytotherapeutic product line developed by Aboca, specifically formulated to support physiological intestinal transit and alleviate constipation. The primary active components are hydroxyanthracene derivatives, such as sennosides and aloin, sourced from Senna and Aloe. These compounds function as stimulant laxatives; upon reaching the colon, they are metabolized by microbiota into active anthrones that stimulate the myenteric plexus, increasing peristaltic contractions and promoting the secretion of water and electrolytes into the intestinal lumen. To mitigate the cramping often associated with stimulant laxatives, Sollievo includes carminative herbs like Fennel, Caraway, and Cumin, which aid in the elimination of intestinal gas. It is marketed as a natural solution for digestive regularity and is available in various forms, including tablets and herbal teas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sollievo.